Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Epigenetic drug for treating osteosarcoma

An osteosarcoma and drug technology, applied in the field of medicine, can solve the problem of not making obvious progress, and achieve the effects of inhibiting the growth and metastasis of osteosarcoma cells, reducing drug side effects, and improving anti-tumor efficacy.

Inactive Publication Date: 2018-08-31
徐州维康生物科技有限公司
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The clinical trials of new drugs for osteosarcoma have not made significant progress, and it is urgent to explore new ideas for drugs for the treatment of osteosarcoma

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Epigenetic drug for treating osteosarcoma
  • Epigenetic drug for treating osteosarcoma
  • Epigenetic drug for treating osteosarcoma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] GSK-J4 is prepared according to different concentrations and ready for use.

[0022] The effects of different concentrations of GSK-J4 on the proliferation of human osteosarcoma cells 143B, MG63, MNNG, SJSA1 and U2 were tested by MTT assay. 143B (ATCC No. CRL-8303) will be in a period of exponential growth TM , human source, epithelioid adherent growth), MG63 (ATCC number CRL-1427 TM , human source, epithelioid adherent growth), MNNG (ATCC number CRL-1547 TM , human source, epithelioid adherent growth), SJSA1 (ATCC number CRL-2098 TM , human, epithelioid adherent growth) and U-2OS cells (ATCC number HTB-96 TM , human source, epithelial-like adherent growth), were digested with trypsin, blown into a single cell suspension, counted, and inoculated into a 96-well culture plate. Cultivate in the incubator for 24 hours. After the cells adhere to the wall, add different concentrations of GSK-J4 (purchased from Selleck, product number S7070), and stop the culture after 48 ...

Embodiment 2

[0027] Using animal models to verify that GSK-J4 has an inhibitory effect on the growth of osteosarcoma. In the experiment, 6-week-old female nude mice were purchased from the Guangdong Experimental Animal Center, weighing between 15 and 20 g, and were reared in separate cages under the condition of no special pathogenic bacteria (SPF), with 12 hours of alternating light and free food and drink. Osteosarcoma cells 143B and SJSA1 were cultured in DMEM high-glucose medium containing 10% high-quality fetal bovine serum until the logarithmic growth phase was used for experiments. When the cells cover the bottom of the culture flask, digest the cells with 5% trypsin, stop the digestion with high-quality fetal bovine serum, blow gently until the cells are completely detached from the wall, centrifuge at 1500 rpm for 5 minutes, and discard the supernatant. The cells were then washed twice with saline. After washing, resuspend the cells in normal saline and adjust the cell concentrat...

Embodiment 3

[0031] Transwell assay was used to verify that GSK-J4 inhibited the metastasis of osteosarcoma cells 143B and SJSA1 ( image 3 ).

[0032] Take a 24-well plate, add 24 Transwell chambers, divide into 8 groups, 4 groups for each type of cells, and each group has 3 replicate wells. Add 50 μL of BD matrigel to each small chamber in turn, add 50 μL of serum-free DMEM medium after it solidifies, and then inoculate 143B or SJSA1 cells in the logarithmic growth phase in the small chambers in turn, and each well contains 50 μL of medium containing 2×10 4 cells. GSK-J4 was added to the upper chamber of Tranwell, the concentrations from left to right were 0μM, 2.5μM, 5μM and 10μM. 500 μL of cell culture medium containing 10% fetal bovine serum was slowly added along the well walls of the 24-well plate, and cultured in a 5% CO2, 37°C constant temperature and humidity incubator for 24 hours. After the end of the experiment, remove the medium in the Transwell chamber and the well in tu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses the application of an inhibitor GSK-J4 of histone demethylase to preparation of a therapeutic drug for osteosarcoma. That histone deemthylase KDM5B is associated with the treatment of the osteosarcoma is proved for the first time. GSK-J4 acts on the histone demethylase KDM5B to significantly inhibit proliferation of osteosarcoma cells, and therefore, can be used as a new breakthrough for preparing a drug for treating the osteosarcoma. Besides, the invention also discloses the ability of the GSK-J4 for inhibiting transfer of the osteosarcoma cells by targeting the KDM5Bfor the first time, and provides a novel idea for researching and developing a drug for treating lung metastasis and osseous metastasis of the osteosarcoma.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to the application of a histone demethylase inhibitor in the preparation of osteosarcoma treatment drugs. Background technique [0002] Osteosarcoma, also known as osteogenic sarcoma, refers to a malignant connective tissue tumor in which tumor cells can directly produce tumor bone and bone-like tissue. Its incidence rate occupies the first place among primary malignant tumors and is the most common malignant osteogenic tumor. one of the tumors. The tumor has a high degree of malignancy, and the prognosis is very poor. It can metastasize to the lungs within a few months, and the survival rate within 3 to 5 years after amputation is only 5 to 20%. Tumors are mostly at the end of the bone, and occasionally occur in the diaphysis or epiphysis. Occurring in the lower end of the femur and the upper end of the tibia account for about three-quarters of all osteosarcomas, and other place...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/55A61P35/00
Inventor 赵蔚邹昌业鲁冰
Owner 徐州维康生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com